

ModernGraham Valuation

Mettler-Toledo
International Inc.



Company Name:

Company Ticker MTD

Date of Analysis

6/5/2018

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

1. Adequate Size of the Enterprise	Market Cap > \$2Bil	\$14,580,337,829	Pass
2. Sufficiently Strong Financial Condition	Current Ratio > 2	1.46	Fail
3. Earnings Stability	Positive EPS for 10 years prior		Pass
4. Dividend Record	Dividend Payments for 10 years prior		Fail
	Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end	142.47%	Pass
5. Earnings Growth	PEmg < 20	36.39	Fail
6. Moderate PEmg Ratio	PB Ratio < 2.5 OR PB*PEmg < 50	26.72	Fail
7. Moderate Price to Assets			

Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.

1. Sufficiently Strong Financial Condition	Current Ratio > 1.5	1.46	Fail
2. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	3.37	Fail
3. Earnings Stability	Positive EPS for 5 years prior		Pass
4. Dividend Record	Currently Pays Dividend		Fail
5. Earnings Growth	EPSmg greater than 5 years ago Score		Pass

Suitability

Defensive	No
Enterprising	No

Stage 2: Determination of Intrinsic Value

EPSmg	\$15.78
MG Growth Estimate	9.04%
MG Value	\$419.34
MG Value based on 3% Growth	\$228.78
MG Value based on 0% Growth	\$134.11
Market Implied Growth Rate	13.95%

MG Opinion

Current Price	\$574.19
% of Intrinsic Value	136.93%
Opinion	Overvalued
MG Grade	D

Stage 3: Information for Further Research

Net Current Asset Value (NCAV)	-\$39.23
Graham Number	\$98.52
PEmg	36.39
Current Ratio	1.46
PB Ratio	26.72
Current Dividend	\$0.00
Dividend Yield	0.00%
Number of Consecutive Years of Dividend Growth	0

Useful Links:

ModernGraham tagged articles	Morningstar
Google Finance	MSN Money
Yahoo Finance	Seeking Alpha
GuruFocus	SEC Filings

EPS History		EPSmg History	
Next Fiscal Year Estimate	\$20.13	Next Fiscal Year Estimate	\$15.78
Dec2017	\$14.24	Dec2017	\$13.22
Dec2016	\$14.22	Dec2016	\$12.29
Dec2015	\$12.48	Dec2015	\$10.97
Dec2014	\$11.44	Dec2014	\$9.85
Dec2013	\$9.96	Dec2013	\$8.64
Dec2012	\$9.14	Dec2012	\$7.65
Dec2011	\$8.21	Dec2011	\$6.64
Dec2010	\$6.80	Dec2010	\$5.65
Dec2009	\$5.03	Dec2009	\$4.84
Dec2008	\$5.79	Dec2008	\$4.45
Dec2007	\$4.70	Dec2007	\$3.56
Dec2006	\$3.86	Dec2006	\$2.86
Dec2005	\$2.52	Dec2005	\$2.30
Dec2004	\$2.37	Dec2004	\$2.13
Dec2003	\$2.11	Dec2003	\$1.93
Dec2002	\$2.21	Dec2002	\$1.73
Dec2001	\$1.68	Balance Sheet Information 3/1/2018	
Dec2000	\$1.66	Total Current Assets	\$927,372,000
Dec1999	\$1.16	Total Current Liabilities	\$636,882,000
Dec1998	\$0.92	Long-Term Debt	\$978,715,000
		Total Assets	\$2,511,907,000
		Intangible Assets	\$769,511,000
		Total Liabilities	\$1,951,160,000
		Shares Outstanding (Diluted Average)	26,096,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other ModernGraham posts about the company [Mettler-Toledo International Inc Valuation – Initial Coverage \\$MTD](#)

Other ModernGraham posts about related companies [DaVita Inc Valuation – June 2018 \\$DVA](#)
[Danaher Corp Valuation – May 2018 \\$DHR](#)
[Agilent Technologies Inc Valuation – May 2018 \\$A](#)
[Cooper Companies Inc Valuation – May 2018 \\$COO](#)
[Edwards Lifesciences Corp Valuation – May 2018 \\$EW](#)
[Baxter International Inc Valuation – May 2018 \\$BAX](#)
[Boston Scientific Corp Valuation – May 2018 \\$BSX](#)
[Centene Corp Valuation – May 2018 \\$CNC](#)
[Abbott Laboratories Valuation – May 2018 \\$ABT](#)
[Becton Dickinson and Co Valuation – May 2018 \\$BDX](#)